Endoscopic evaluation of the comparative effects of acetylsalicylic acid and choline magnesium trisalicylate on human gastric and duodenal mucosa.
A new salicylate product, choline magnesium trisalicylate (Trilisate tablets), and acetylsalicylic acid were compared for their local effects in equipotent doses on the gastroduodenal mucosa in a randomized, double-blind, cross-over study, using 10 healthy volunteers. After five-day periods of administration, gastroduodenoscopy was performed and photographs were obtained. All subjects given acetylsalicylic acid developed multiple mucosal lesions, but in only four subjects given choline magnesium trisalicylate were slight mucosal changes noted. Mean serum salicylate levels were similar in the two groups. Our data suggest that the risk of developing mucosal lesions is much less during treatment with choline magnesium trisalicylate than with acetylsalicylic acid.
D000328:Adult; D000893:Anti-Inflammatory Agents; D001241:Aspirin / Q000009:adverse effects / Q000494:pharmacology*; D002794:Choline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004386:Duodenum / Q000187:drug effects* / Q000473:pathology; D004724:Endoscopy; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012459:Salicylates / Q000009:adverse effects / Q000494:pharmacology*
D000893:Anti-Inflammatory Agents; D012459:Salicylates; C017959:choline magnesium trisalicylate; D002794:Choline; D001241:Aspirin